Sanderling has supported over 90 biomedical companies earning consistently high rates of return on its venture investments.
Investors 1
Mentions in press and media 19
| Date | Title | Description |
| 26.11.2016 | Chiesi Ventures Joins $12M Series A for Glycomine | Glycomine, Inc. a biotechnology company developing a new generation of replacement therapies for rare diseases, announced that it has raised $12 million in a Series A financing led by Sanderling Ventures and supported by Chiesi Ventures as ... |
| 10.10.2013 | No catheter, no cuff: FDA clears Sotera Wireless’ continuous noninvasive blood pressure technology | The ViSi Mobile System, a wrist-worn monitor that measures vital signs and is designed to be used in ambulatory, non-ICU clinical settings, and was FDA-cleared in 2012. The company also boasts partnerships with Intermountain Health and Refl... |
| 05.09.2013 | BDC and FTQ Pour Major Investment into New Montreal Biomedical Fund | Money seems to be flying around Montreal these days. The Business Development Bank of Canada (BDC) and the Fonds de Solidarité du Quebec (FTQ) have announced a $30 million commitment to US-based Sanderling Ventures, an investment firm with ... |
| 13.12.2011 | Sotera Wireless Completes $12.2M Series D Financing | Sotera Wireless, Inc., a San Diego CA-based medical device company, completed a $12.2m Series D financing. The round was led by Singapore-based global fund, EDBI, with participation from new investor Cerner Capital and existing investors Sa... |
| 18.08.2010 | Cancer drug developer Endocyte files for $86M IPO | Endocyte’s small-molecule drug conjugates “actively target receptors that are over-expressed on diseased cells,” the company said in its registration statement. This targeting enables patients to be treated with highly active drugs or high ... |
| 04.08.2010 | Cancer drugmaker Gemin X closes $8M Series E round | It’s unclear when Gemin X will begin its Phase 3 trial, but it’s safe to say it won’t happen this year, a company spokeswoman said. Gemin X’s latest fundraise brings the total amount of equity it’s brought in to $120 million since the compa... |
| 07.04.2010 | Torax Medical wins CE Mark for GERD device | By Brandon Glenn Torax Medical Inc. won CE Mark approval in the European Union for an implantable device that treats patients suffering from acid-reflux disease. The company’s Linx device is intended for patients with gastro-esophageal refl... |
| 07.04.2010 | Torax Medical gets European OK for acid reflux disease device | The device has not yet been cleared for U.S. sales. In September, Torax completed patient enrollment in a “pivotal” clinical trial that could be the springboard for approval by the Food and Drug Administration, according to Mark Stultz, sen... |
| 16.10.2009 | Cancer drug business Endocyte raises $26 million | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 16.04.2008 | Xytis gets $7.5M to work on central nervous system disorders | Xytis, a privately-held biotech company based in both the U.S. (Irvine, CA) and Europe (London, England and Nyon, Switzerland) has raised a new round of series B funding. The company specializes in making treatments for patients with centra... |
Show more